Tag: Biofourmis
Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain
Chugai Pharmaceutical, one of Japan’s leading research-based pharmaceutical companies and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis. Read more Wearables In Combination With Digital Technology Offers Huge Opportunities For Non-Invasive Pain Management Endometriosis is the repeated proliferation […]
Biofourmis’ AI-Powered Tech Being Used in Remote Monitoring of COVID-19 Patients in Hong Kong
Biofourmis, a developer of digital therapeutics that powers personalized predictive care, announced that its technology is being leveraged in a remote monitoring and disease surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19). The program, administered by The University of Hong Kong, also includes Hong Kong-based Harmony Medical Inc., […]
Biofourmis Collaborates with ImagineMIC to Improve Remote Patient Monitoring for Chronic Disease Patients
Biofourmis, a fast-growing global health IT start-up founded in Singapore, and ImagineMIC, a New York-based medical device company formed a partnership to drive improved outcomes and lower healthcare costs for patients with chronic conditions. ImagineMIC provides chronic care management through remote monitoring services and HIPAA-compliant technology. Read More Biofourmis to Partner with Yale University-Mayo Clinic […]
Biofourmis Buys Biovotion to Deliver Precise Interventions for Patients with Complex Chronic Conditions
US-based digital therapeutics company Biofourmis has signed an agreement to buy Zurich, Switzerland-based wearable biosensor company Biovotion. The deal consists of all Biovotion’s assets, including the clinical-grade Everion® device and over 60 global patents. Read more Fighting Against NCDs – Wearables for Chronic Disease Management and Mobility Challenges The acquisition of Biovotion enables Biofourmis to […]
Biofourmis to Partner with Yale University-Mayo Clinic Collaborative Program CERSI
Biofourmis, a global leader in digital therapeutics, has entered a research partnership with Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). The study, which involves patients with heart failure, will leverage Biofourmis’ mobile platform BiovitalsHFTM to see if greater emphasis should be placed on functional capacity and quality of life of […]
FDA Clears Biofourmis’ AI-Driven Arrhythmia Detection Platform RhythmAnalytics
Biofourmis, a Singapore-based health-tech startup, has received FDA clearance for its cloud-based software, RhythmAnalytics, which helps healthcare professionals in detecting cardiac arrhythmia, or irregular heartbeat. The cloud-based software uses enhanced deep learning to detect over 15 types of cardiac arrhythmia with beat-by-beat morphology computation that includes ventricular arrhythmias, ventricular ectopic beats and all non-paced arrhythmias […]